Mounjaro vs. Zepbound: Same Medication, Different Indications
Both Mounjaro and Zepbound contain tirzepatide, but they're approved for different conditions. Understand the key differences in approvals, coverage, and usage.
Mounjaro and Zepbound are both brand names for tirzepatide manufactured by Eli Lilly, but they serve different FDA-approved purposes. Understanding the distinctions is important for patients and providers.
The Basics
| Feature | Mounjaro | Zepbound |
|---|---|---|
| Active Ingredient | Tirzepatide | Tirzepatide |
| Manufacturer | Eli Lilly | Eli Lilly |
| FDA Approval Date | May 2022 | November 2023 |
| Indication | Type 2 Diabetes | Chronic Weight Management |
| Available Doses | 2.5-15 mg | 2.5-15 mg |
| Administration | Weekly injection | Weekly injection |
Key Differences
1. FDA-Approved Indication
- Mounjaro: Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise
- Zepbound: Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity
2. Insurance Coverage
- Mounjaro: Generally better insurance coverage due to diabetes classification
- Zepbound: Coverage for obesity is less consistent; many plans exclude weight management medications
3. Prescribing Context
- Mounjaro: Typically prescribed by endocrinologists and primary care providers managing diabetes
- Zepbound: May be prescribed by obesity medicine specialists, primary care, or through telehealth weight management services
Can You Use Mounjaro for Weight Loss?
While Mounjaro is only FDA-approved for type 2 diabetes, physicians can prescribe it "off-label" for weight loss. This was common before Zepbound's approval and still occurs. However, insurance is unlikely to cover off-label use for weight loss.
Clinical Trial Populations
The clinical trial populations differed:
- SURPASS (Mounjaro): Patients with type 2 diabetes
- SURMOUNT (Zepbound): Patients with obesity/overweight, with and without diabetes
Both populations showed significant weight loss, but the SURMOUNT trials specifically studied weight as the primary endpoint.
Which Should You Ask About?
- If you have type 2 diabetes → Ask about Mounjaro
- If your primary goal is weight loss without diabetes → Ask about Zepbound
- If you have both diabetes and want weight loss → Either may be appropriate; discuss with your provider